NCT02317861View on ClinicalTrials.gov

A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

Gout and Asymptomatic Hyperuricemia

Interventions

DRUG

RDEA3170

Oral Treatment

DRUG

Febuxostat

Oral Treatment

DRUG

Benzbromarone

Oral Treatment

Trial Locations (1)

Unknown

Research Site, Fukuoka

Sponsors

Lead Sponsor

Collaborators (1)

Ardea Biosciences, Inc.

All Listed Sponsors

collaborator

Ardea Biosciences, Inc.

INDUSTRY

lead

AstraZeneca

INDUSTRY